← Back to Search

Combination Therapy

full dose lat dor-tim; tim-brim-dor-bim for Glaucoma

Phase 4

Recruiting

Led By Peter E Libre, MD

Research Sponsored by CT Glaucoma Associates

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 weeks after each phase

Awards & highlights

Study Summary

"This trial will compare the effects of using half the normal dose of latanoprost dorzolamide-timolol with the full dose. It will also compare the combination of timolol

Who is the study for?

This trial is for individuals with glaucoma, including open-angle type. Specific eligibility details are not provided, but typically participants would need to meet certain health criteria and not have conditions that could interfere with the study or pose a risk.Check my eligibility

What is being tested?

The trial is testing if half-doses of latanoprost combined with dorzolamide-timolol can manage eye pressure as effectively as full doses. It also compares these treatments to another combination: timolol-brimonidine-dorzolamide-bimatoprost.See study design

What are the potential side effects?

Potential side effects may include dry eyes and other common reactions to glaucoma medications such as redness, discomfort, blurred vision, eyelash growth changes, or darkening of the iris.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 weeks after each phase

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 weeks after each phase

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks after each phase for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

intraocular pressure

Secondary outcome measures

dry eye

Trial Design

2Treatment groups

Active Control

Group I: full dose lat dor-tim; tim-brim-dor-bimActive Control1 Intervention

After baseline IOP measurements, subjects in this arm will use the full dose full dose latanoprost and dorzolamide-timolol in phase 2, and then timolol-brimonidine-dorzolamide-bimatoprost in phase 3.

Group II: tim-brim-dor-bim; full dose lat dor-timActive Control1 Intervention

After baseline IOP measurements, subjects in this arm will use timolol-brimonidine-dorzolamide-bimatoprost in phase 2, and then full dose latanoprost and dorzolamide-timolol in phase 3.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

CT Glaucoma AssociatesLead Sponsor

Peter E Libre, MDPrincipal InvestigatorCT Glaucoma Associates

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Am I eligible to be a part of this medical study?

"Individuals eligible for participation in this research study must have a diagnosis of glaucoma and fall within the age range of 25 to 90 years. The trial aims to enroll approximately 60 participants."

Answered by AI

What is the total number of subjects actively involved in this research investigation?

"Yes, information displayed on clinicaltrials.gov shows that this trial is currently seeking participants. Initially shared on April 1st, 2024, and last modified on April 15th, 2024, the study aims to enroll a total of 60 patients across one designated site."

Answered by AI

Is there inclusion of individuals above the age of 70 in this research study?

"Patients eligible for this study must be aged between 25 and 90 years. While there are 14 trials specifically targeting individuals under 18, there are also a substantial 191 studies focused on those over the age of retirement."

Answered by AI

Are researchers currently enrolling participants for this study?

"Indeed, the details on clinicaltrials.gov show that this trial is currently seeking participants. The trial was first listed on 4/1/2024 and most recently updated on 4/15/2024. Recruitment aims to enlist a total of 60 individuals from a single site."

Answered by AI

What are the safety implications of administering tim-brim-dor-bim at the maximum recommended dosage for individuals?

"The safety rating for the full-dose lat dor-tim medication, also known as tim-brim-dor-bim, has been designated a level of 3 by our team at Power. This decision is influenced by the fact that this trial falls under Phase 4, indicating regulatory approval for its use."

Answered by AI